GHK-Cu

Overview

[educational] Main mechanism is gene regulation, NOT copper transport — positively regulates ~32% of human genes (4,000+) toward a youthful state (plus direct protein actions). Plasma ~200 ng/mL at 20 → ~80 at 60. — GHK-Cu deep dive

[literature-animal] Animal wound-repair data (like BPC); a Chinese group is studying it for lung regeneration (COPD / possible long-COVID connective-tissue repair). — Bakri 01:54
[educational] Seven effect areas: skin regen (best-evidenced; RCTs ↓wrinkles, diabetic-ulcer 60→98% closure), hair (≈/>minoxidil mice; +50% transplant regrowth), anti-inflammatory (↓NF-κB, IL-6/TNF-α) + antioxidant (↑Nrf2→SOD), tissue healing (gut via SIRT1/tight-junctions, lung COPD/fibrosis/asthma, liver, MSK<BPC/TB-4), potential anti-cancer (pro-apoptosis/anti-metastasis), cardiovascular (↓fibrinogen), neuroprotection (anti-misfolding, NGF). Mostly in-vitro/animal; human end-data thin. — GHK-Cu deep dive

[anecdote] Copper tripeptide (Gly-His-Lys + Cu²⁺) in type-1 collagen (Pickart); serum falls ~200 → 60 ng from youth to 65; regulates both collagen synthesis and breakdown. A genuine product is blue (copper) — though blue ≠ proof of an intact complex. Basis of the ‘glow stack’ (Wolverine + GHK). — Bakri 01:51–01:52
[anecdote-bb] Used for localized collagen / ‘site enhancement’ by injection (e.g. triceps sweep) — effective but very painful, needs deep-tissue massage to break up collagen filaments; topical useful for skin and dissolving calluses. Panel felt GH outperformed it. — Anabolic Roundtable ~01:13–01:19

[protocol] Best human data is topical (vs retinol/vitamin-C), synergistic with red-light therapy, used as an adjunct to a skincare routine — not injected into the face. Hair effect modest (adjunct to minoxidil). Injectable not FDA-approved. — Bakri 01:53–02:18
[protocol] Topical for skin/hair (beats subQ for those — concentrates at target): 0.5–2% conc., start 0.5% thin layer once daily; prefer a compounding-pharmacy product (pH-sensitive, hydrophilic → quality matters); boost with micro-needling (q2–4 wk) + hyaluronic-acid pre-hydration. SubQ for systemic/longevity/MSK: start 0.5 mg/day, titrate to ~1 mg (max 2); daily > every-other-day. Cycles: topical ~indefinite; subQ ~3–4 wk on / 1–2 wk off. — GHK-Cu deep dive

[warning] Injection-site stinging (copper) → dilute, inject slowly, split sites. Copper-toxicity risk low (2 mg GHK-Cu ≈ 0.314 mg Cu vs 10 mg upper limit) but monitor serum/free copper, ceruloplasmin, RBC Cu/Zn, iron, liver enzymes, hs-CRP; screen Wilson’s disease. Leans anti-cancer but avoid in active cancer. Injectable not FDA-approved; topical not banned. — GHK-Cu deep dive
[regulatory] US status shifting (2026): injectable GHK-Cu was among the ~12 peptides removed from FDA Category 2 (Feb 2026). Note it is not on the July 23–24 2026 PCAC 503A agenda (which covers BPC-157/TB-500/MOTS-c/KPV/DSIP/Semax/Epitalon) — so its 503A path is not yet under active review. Not FDA-approved (injectable); topical unaffected. — SOURCE-fda-pcac-503a-peptide-review-2026